SATURDAY, OCTOBER 21, 2017

Curcumin may help fight drug-resistant tuberculosis

Curcumin, which is found in turmeric and is one of the major elements in curry powder, may be able to help treat people who have infections of drug-resistant tuberculosis. Read More »

GenScript accelerates Zika virus vaccine development

GenScript, a global supplier of gene-synthesis services, is rushing to develop and deliver DNA constructs as part of the response against the recent outbreak of Zika virus. Read More »

WHO to evaluate Merck's Ebola vaccine candidate

The World Health Organization (WHO) intends to evaluate the Emergency Use Assessment and Listing (EUAL) application for an investigational Ebola vaccine that has been developed by Merck. Read More »

WHO accepts Merck's Ebola vaccine for emergency use

Merck Pharmaceuticals' Ebola Zaire vaccine, V920, was recently accepted for review by the World Health Organization (WHO) for Emergency Use Assessment and Listing (EUAL). Read More »

BMJ study shows allergic and asthmatic children can benefit from flu vaccine

A recent study from The BMJ shows that the influenza vaccine for children is not likely to cause any allergic reaction if the child has well-controlled asthma, a recurrent wheeze, or an egg allergy. Read More »

Sanofi introduces new packaging for Priftin

Sanofi recently introduced its new packing for Priftin (rifapentine) specially for treating latent tuberculosis infections (LTBI) in people who are 2 or older and have a high risk of developing tuberculosis (TB). Read More »

Chinese officials report nosocomial bird flu transmission

Health professionals may have located the first evidence of a transmission the avian influenza A (H7N9) virus between unrelated people in a hospital in China. Read More »

Company commits to help Nigeria with diarrhea and malaria prevention

Consumer health and hygiene company Reckitt Benckiser (RB) recently committed itself to helping Nigeria with its prevention efforts against diarrhea and malaria. Read More »

Merck shows dedication in 40 conference presentations

Merck, which is called MSD outside of Canada and the U.S., recently announced that its representatives will be giving over 40 presentations that demonstrate the dedication of the company to treating infectious diseases. Read More »

ADMA Biologics receives patent for immunodeficiency treatment

ADMA Biologics, Inc., a late-stage biopharmaceutical company, said Monday it has received a patient for its treatment of immunodeficiency. Read More »

Cell phone data to monitor spread of infectious diseases

Vast datasets from tracking mobile phone data could allow health professionals to track the infectious diseases that spread each season. Read More »

Back-to-school vaccines are for more than just students

The back-to-school season is a yearly reminder for parents to verify that their children have been vaccinated, but adults are also encouraged to use the back-to-school season to update their own immunizations. Read More »

Australia grants Zoetis' new Hendra virus vaccine full registration

Zoetis recently announced that the Australia Pesticides and Veterinary Medicines Authority (APVMA) has granted full registration for Equivac HeV, a vaccine for the Hendra virus. Read More »

Merck celebrates 30 years in HIV/AIDS innovation and care

Merck, known as MSD outside of Canada and the U.S., recently announced that it now has been committed to innovation and care in HIV/AIDS for 30 years. Read More »

Longboat gives Greater Gift Initiative 980 vaccines

The Greater Gift Initiative (GGI) recently announced that it has received 980 vaccines by means of a donation from Longboat. Read More »

Catalent gets grant, joins effort to improve vaccine properties

Catalent -- a global provider of advanced delivery technologies, as well as development solutions, for biologics, drugs and consumer health products -- recently said it has accepted a grant as part of a consortium to fund the research, development and production of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Read More »

Quadrivalent seasonal influenza vaccine candidate advances to Phase 2 testing

VaxInnate Corp., a biotechnology company creating a novel vaccine technology platform, recently announced that it has started a double-blind, randomized, active comparator controlled Phase 2 study for a quadrivalent seasonal influenza vaccine candidate. Read More »

HPV vaccine successfully heat stabilized

According to a recent announcement from Soligenix Inc., the company has successfully applied its heat-stabilization technology to its human papillomavirus (HPV) vaccine. Read More »

Researchers create heat-stable Ebola vaccine

According to a recent announcement, Soligenix Inc. -- a late-stage biopharmaceutical company that creates products for inflammation, biodefense and oncology, as well as other similar unmet medical needs -- has partnered with the University of Hawaii at Manoa and Hawaii Biotech to create an Ebola vaccine that is heat stable. Read More »

US citizen traveling from Liberia dies from Lassa fever

Health professionals from the New Jersey Department of Health and the Centers for Disease Control and Prevention (CDC) recently confirmed that a U.S. traveler returning from Liberia died from Lassa fever. Read More »